Janux Therapeutics, Bristol Myers enter up to $850 million deal to develop cancer drug

Core Insights - Janux Therapeutics has announced a collaboration with Bristol Myers Squibb to develop a new cancer treatment, which has resulted in a more than 12% increase in its shares during premarket trading [1] Company Summary - Janux Therapeutics is engaging in a partnership with Bristol Myers Squibb aimed at advancing a new cancer therapy [1] - The announcement of this collaboration has positively impacted Janux Therapeutics' stock performance, reflecting investor optimism [1]